Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oliceridine effect on remifentanil EC50 during general anesthesia intubation
ChiCTR2400091591Phase 4Not yet recruiting
- Sponsor
- Fuling Central Hospital
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of oliceridine and remifentanil (2 arms), sponsored by Fuling Central Hospital. Primary endpoint: Half effective concentration (EC50) of remifentanil for satisfactory intubation conditions without significant tracheal intubation response. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
oliceridineremifentanil
Beyond the preview
Go deeper on ChiCTR2400091591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091591.